On May 5, 2022 EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy-based therapies, reported that the company will be showcasing and exhibiting its Focal One Robotic High Intensity Focused Ultrasound (HIFU) platform at the upcoming Annual Meeting of the American Urological Association (AUA), the largest gathering of urologists worldwide, which will be held May 13th through 15th in New Orleans (Press release, EDAP TMS, MAY 5, 2022, View Source [SID1234613698]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Focal One will be a featured topic at AUA, during both plenary presentations and instructional courses. Several notable presentations will be given by leading academic centers describing the growing clinical acceptance of the role of focal therapy in the management of prostate cancer. An AUA hands-on skills training will be teaching urologists how to implement focal treatments in their practice and will allow them to utilize Focal One under the guidance of expert faculty.

Ryan Rhodes, CEO of EDAP U.S., said, "We are very pleased to have such a notable presence at AUA, the most high-profile urology meeting of the year. Focal therapy is quickly becoming a necessary prostate cancer treatment option, and we are pleased that many highly regarded healthcare institutions will be on hand to describe their experience to date. We believe Focal One is the most advanced focal therapy platform available today, and we look forward to demonstrating this cutting-edge technology to the many urology thought leaders who will be in attendance."

Ongoing Focal One and ExactVu Micro-Ultrasound hands-on simulations will be provided to urologists at the EDAP Focal One booth (#117) throughout the meeting. ExactVu will be featured in two skill-enhancement workshops about the scientific evidence of microultrasound and the flexibility for transperineal or transrectal approaches.

On May 5, 2022 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, reported it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, May 12, 2022 to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2022 (Press release, Scynexis, MAY 5, 2022, View Source [SID1234613697]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast can be accessed by visiting the Investor Relations section of the Company’s website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.

On May 5, 2022 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences (Press release, Neoleukin Therapeutics, MAY 5, 2022, View Source [SID1234613696]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BofA Securities 2022 Healthcare Conference – Las Vegas, NV

Fireside chat
Wednesday May 11, 2022, at 1:20 p.m. Pacific
H.C. Wainwright Global Investment Conference – Miami, FL

Company presentation
Wednesday, May 25, 2022, at 12:30 p.m. Eastern
The webcast presentations can be accessed from the investors section of the Neoleukin website at View Source Archived replays will also be available on the company website for at least 30 days following the event.

On May 5, 2022 Biogen Inc. (Nasdaq: BIIB) and MedRhythms reported that they have entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis (MS) (Press release, Biogen, MAY 5, 2022, View Source [SID1234613695]). The collaboration combines MedRhythms’ digital expertise with Biogen’s leadership and global footprint in MS in order to address significant unmet patient needs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MedRhythms is developing next-generation prescription digital therapeutics across a broad range of indications in neurology via a technology platform that leverages advancements in neuroscience and music to target improved walking and mobility. MR-004 is MedRhythms’ pipeline candidate in MS, which aims to improve gait and gait-related aspects of movement, potentially providing MS patients with improved independence related to mobility. If approved, MR-004 has the potential to become the first prescription digital therapeutic for gait deficit in MS. MedRhythms is currently conducting two ongoing feasibility studies for MR-004, and, based on the readout of the first study, plans to initiate a registrational trial in the near future.

"As part of our aspiration in digital health, together with MedRhythms we aim to advance a new, innovative treatment option for people living with MS that may help address walking impairment, a common issue that impacts their overall quality of life," said Martin Dubuc, Head of Biogen Digital Health. "Pioneering in digital therapeutics exemplifies Biogen’s commitment to advance novel therapies that we hope will improve outcomes for people living with MS."

"At MedRhythms, we are committed to redefining what is possible for people living with neurologic diseases by building evidence-based products that meaningfully impact symptoms that have been underserved by traditional treatment modalities," said Brian Harris, Chief Executive Officer of MedRhythms. "We look forward to what our collaboration with Biogen, a global leader in MS, could mean for the patients we serve around the world."

Under the terms of the agreement, Biogen will make an upfront payment of $3 million to MedRhythms. Should certain development and commercial milestones be achieved, MedRhythms will be eligible to receive up to $117.5 million in potential milestone payments. MedRhythms is also eligible to receive tiered royalties in the high-single digits to low-teens on potential global sales.

On May 5, 2022 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update (Press release, Altimmune, MAY 5, 2022, View Source [SID1234613694]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Altimmune management will host a conference call at 8:30 am E.T. on May 12 to discuss financial results and provide a business update.